Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.

Biotechnology

Education

Akero

Akero's headquarters in South San Francisco, CA, United States

Andrew Cheng

Scott Gangloff

Kitty Yale

Patrick Lamy

Libette Luce

Brittany de Temple

Dominick Villani

Tim Rolph

William White

Jonathan Young

Catriona Yale

Judy Chou

Mark Iwicki

Graham Walmsley

Seth L. Harrison

Tom Heyman

Yuan Xu

Jane Pritchett Henderson

Description

People (8)

Maribel Rios

Vaisali Viswanathan Panyam

Eva Rankers

Yasmine Rafidi

Jimmie Zhang

Ali Moulton

Kitty Yale

Dr. Judy Chou

Jobs